Education
About Us
Working with TipRanks
Follow Us
Takeda Pharmaceutical Company (TAK)
NYSE:TAK
RESEARCH TOOLSreports
Total Valuation
Takeda Pharmaceutical Company has a market cap or net worth of $46.22B. The enterprise value is $70.87B.
Market Cap$46.22B
Enterprise Value$70.87B
Share Statistics
Takeda Pharmaceutical Company has 3.18B shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding3.18B
Owned by Insiders
Owned by Instutions0.03%
Financial Efficiency
Takeda Pharmaceutical Company’s return on equity (ROE) is 0.02 and return on invested capital (ROIC) is 4.44%.
Return on Equity (ROE)1.98%
Return on Assets (ROA)0.95%
Return on Invested Capital (ROIC)4.44%
Return on Capital Employed (ROCE)1.67%
Revenue Per Employee$92,248,188.957
Profits Per Employee$5,884,539.681
Employee Count49,281
Asset Turnover0.28
Inventory Turnover1.18
Valuation Ratios
The current PE Ratio of Takeda Pharmaceutical Company is 45.02. Takeda Pharmaceutical Company’s PEG ratio is -0.82.
PE Ratio45.02
PS Ratio1.52
PB Ratio0.89
Price to Fair Value0.89
Price to FCF27.53
Price to Operating Cash Flow9.05
PEG Ratio-0.82
Income Statement
In the last 12 months, Takeda Pharmaceutical Company had revenue of $4.55T and earned $290.00B in profits. Earnings per share was $184.31.
Revenue$4.55T
Gross Profit$2.51T
Operating Income$509.41B
Pretax Income$266.68B
Net Income$290.00B
EBITDA1.24T
Earnings Per Share (EPS)184.31
Cash Flow
In the last 12 months, operating cash flow was $837.30B and capital expenditures -$328.72B, giving a free cash flow of $508.58B billion.
Operating Cash Flow$837.30B
Free Cash Flow$508.58B
Free Cash Flow per Share$159.83
Dividends & Yields
Takeda Pharmaceutical Company pays an annual dividend of $0.32, resulting in a dividend yield of 4.03%
Dividend Per Share$0.32
Dividend Yield4.03%
Payout Ratio149.66%
Free Cash Flow Yield7.27%
Earnings Yield2.22%
Stock Price Statistics
Beta0.10
52-Week Price Change15.90%
50-Day Moving Average14.26
200-Day Moving Average13.65
Relative Strength Index (RSI)54.00
Average Volume (3m)2.13M
Important Dates
Takeda Pharmaceutical Company upcoming earnings date is May 8, 2025, Before Open.
Last Earnings DateJan 30, 2025
Next Earnings DateMay 8, 2025
Ex-Dividend DateMar 31, 2025
Financial Position
Takeda Pharmaceutical Company as a current ratio of 1.11, with Debt / Equity ratio of 0.67
Current Ratio1.11
Quick Ratio0.58
Debt to Market Cap0.75
Net Debt to EBITDA5.01
Interest Coverage Ratio1.39
Taxes
In the past 12 months, Takeda Pharmaceutical Company has paid -$20.45B in taxes.
Income Tax-$20.45B
Effective Tax Rate-173.15%
Enterprise Valuation
Takeda Pharmaceutical Company EV to EBITDA ratio is 8.72, with an EV/FCF ratio of 32.38.
EV to Sales1.79
EV to EBITDA8.72
EV to Free Cash Flow32.38
EV to Operating Cash Flow10.65
Balance Sheet
Takeda Pharmaceutical Company has $906.22B in cash and marketable securities with $5.05T in debt, giving a net cash position of $4.14T billion.
Cash & Marketable Securities$906.22B
Total Debt$5.05T
Net Cash$4.14T
Net Cash Per Share$1.30K
Tangible Book Value Per Share-$1.54K
Margins
Gross margin is 66.43%, with operating margin of 5.02%, and net profit margin of 3.38%.
Gross Margin66.43%
Operating Margin5.02%
Pretax Margin1.24%
Net Profit Margin3.38%
EBITDA Margin20.51%
EBIT Margin4.04%
Analyst Forecast
The average price target for Takeda Pharmaceutical Company is $36.71, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
Price Target$36.71
Price Target Upside150.58%
Analyst ConsensusModerate Buy
Analyst Count0
Revenue Growth Forecast1.92%
EPS Growth Forecast6.40%